Proparacaine

Generic Name
Proparacaine
Brand Names
Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
Drug Type
Small Molecule
Chemical Formula
C16H26N2O3
CAS Number
499-67-2
Unique Ingredient Identifier
B4OB0JHI1X
Background

Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication

Used as a local (ophthalmic) anesthetic.

Associated Conditions
Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Associated Therapies
Local Anaesthesia therapy
Clinical Trials
Related News

Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

First Posted Date
2010-03-24
Last Posted Date
2024-11-06
Lead Sponsor
Fondazione EMN Italy Onlus
Target Recruit Count
389
Registration Number
NCT01091831
Locations
🇮🇹

Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

First Posted Date
2010-03-17
Last Posted Date
2021-03-18
Lead Sponsor
Gilead Sciences
Target Recruit Count
241
Registration Number
NCT01088048
Locations
🇺🇸

Center for Cancer and Blood Disorders, Bethesda, Maryland, United States

🇺🇸

Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States

🇺🇸

Clearview Cancer Institute, Huntsville, Alabama, United States

and more 8 locations

Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q

Phase 2
Completed
Conditions
Myelodysplastic Syndromes
Interventions
Drug: Lenalidomide
First Posted Date
2010-03-05
Last Posted Date
2024-02-23
Lead Sponsor
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Target Recruit Count
91
Registration Number
NCT01081431
Locations
🇩🇪

Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

🇩🇪

Kath. Klinikum Duisburg, Duisburg, Germany

🇩🇪

Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany

and more 9 locations

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

First Posted Date
2010-03-04
Last Posted Date
2022-09-21
Lead Sponsor
Amgen
Target Recruit Count
792
Registration Number
NCT01080391
Locations
🇺🇸

Providence St. Joseph Medical Center, Burbank, California, United States

🇺🇸

Stanford University, Stanford, California, United States

🇺🇸

Weill Cornell Medical College, New York, New York, United States

and more 123 locations

Lenalidomide and High-Dose Melphalan

First Posted Date
2010-03-03
Last Posted Date
2016-06-06
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
61
Registration Number
NCT01079936
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

First Posted Date
2010-02-26
Last Posted Date
2019-10-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
110
Registration Number
NCT01076543
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

🇺🇸

University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States

and more 8 locations

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

First Posted Date
2010-02-25
Last Posted Date
2020-10-22
Lead Sponsor
Mayo Clinic
Target Recruit Count
58
Registration Number
NCT01075321
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1
Completed
Conditions
Non-Hodgkin's Lymphoma
Interventions
Drug: Lenalidomide
Drug: ofatumumab
First Posted Date
2010-02-02
Last Posted Date
2023-10-04
Lead Sponsor
University of Nebraska
Target Recruit Count
46
Registration Number
NCT01060384
Locations
🇺🇸

Saint Francis Medical Center, Grand Island, Nebraska, United States

🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma

First Posted Date
2010-01-27
Last Posted Date
2022-02-08
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
38
Registration Number
NCT01057121
Locations
🇺🇸

Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States

🇺🇸

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 10 locations

Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

First Posted Date
2010-01-26
Last Posted Date
2018-03-22
Lead Sponsor
University of Cologne
Target Recruit Count
30
Registration Number
NCT01056679
Locations
🇩🇪

1st Dept. of Medicine, Cologne University Hospital, Cologne, NRW, Germany

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy